According to an end-of-2021 SEC filing, the company had 44 employees. The company is working to implement other cost-cutting measures as it ramps up for FDA authorization of its flagship diabetes product.
“My long-term outlook for the potential of our digital therapeutics platform, not just in Type 2 diabetes but potentially many other cardiometabolic diseases, remains unchanged, and I continue to believe that we will demonstrate the significant medical and commercial potential of our therapeutic approach, including the potential to significantly reduce the cost of care associated with chronic metabolic conditions,” CEO Frank Karbe said in an email to employees that was included with the SEC statement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.